Medigen, in collaboration with Taipei Municipal Wanfang Hospital- Managed by Taipei Medical University, has applied for the Autologous Gamma-Delta T Cell cell therapy project. On July 04, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice. In accordance with the regulations of the ?Regulations Governing the Application of Specific Medical Examination Technique and Medical Device?, the Magicell-GDT cells produced at Medigen?s Cell Processing Unit can be used for treating stage IV solid tumors at Taipei Municipal Wanfang Hospital.

Details on the approved items in the above mentioned Taipei Municipal Wanfang Hospital cell therapy project: A. Type of cell therapy: Autologous Gamma-Delta T cell B. Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer C. Cell processing unit: Medigen?s cell processing unit D. Approval period: From July 3, 2024 to February 2, 2026. The manufacturing technology of this approved Gamma-Delta T cell is exclusively licensed from the Japanese listed company MEDINET Co. Ltd.